Merck to start new trial to test Alzheimer's drug
Dec 3 (Reuters) - Merck & Co Inc said on Monday it started a new clinical trial to evaluate the safety and effectiveness of its experimental oral drug MK-8931 in patients with mild-to-moderate Alzheimer's disease.
The Phase II trial, which will compare the drug with a placebo, is a global, multi-center study that includes a group of 200 patients to test safety.
The study is expected eventually enroll up to 1,700 patients in the main Phase III group.
The drug is the first of its kind to advance to this stage of clinical research.
- Israel rejects ceasefire plan, source says as death toll nears 850 |
- First Ebola victim in Sierra Leone capital on the run
- Bad weather seen as probable cause of Air Algerie crash
- White House aide says Republicans might try for Obama impeachment
- EU edges to economic sanctions on Russia but narrows scope |